Perioperative therapy in muscle invasive bladder cancer
Authors:
Open Access
- 1 July 2021
- journal article
- review article
- Published by Medknow in Indian Journal of Urology
- Vol. 37 (3) , 226-233
Abstract
Radical cystectomy with bilateral pelvic lymph node dissection is the standard of care for muscle invasive bladder cancer (MIBC). The role of neoadjuvant and adjuvant therapy has evolved over the last 3–4 decades, and neoadjuvant chemotherapy (NACT) has now become the standard recommended treatment. However, there are many nuances to this and the utilization of chemotherapy has not been universal. The optimum chemotherapy regimen is still debated. Adjuvant radiation has a role in high-risk patients although not established and immunotherapy has shown promising results. We reviewed the evidence on NACT and adjuvant chemotherapy (ACT) regimens, NACT versus ACT, and the role of adjuvant radiotherapy and immunotherapy in MIBC.Keywords
This publication has 56 references indexed in Scilit:
- Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized TrialsEuropean Urology, 2014
- A Novel Risk Stratification to Predict Local-Regional Failures in Urothelial Carcinoma of the Bladder After Radical CystectomyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 StatusJournal of Clinical Oncology, 2011
- Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trialAnnals of Oncology, 2011
- A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2‐T4aN0‐N2M0 bladder cancerCancer, 2011
- Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumoursEuropean Journal of Cancer, 2006
- Complete long‐term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancerBJU International, 2005
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005
- Neoadjuvant Chemotherapy for Transitional Cell Carcinoma of the Bladder: A Systematic Review and Meta-AnalysisJournal of Urology, 2004
- Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder CancerNew England Journal of Medicine, 2003